Search

everythinglearnresearchcommunity

for

Search:↓

Some medications might contribute to male infertility, with finasteride showing a high number of reports.

Pranlukast and mirabegron may work as new diabetes drugs.

Statins may be linked to reproductive organ conditions, and their risks should be monitored.

Paternal drug exposure can harm fertility, pregnancy outcomes, and offspring health, with specific drugs linked to various reproductive issues.

The methods accurately measure finasteride and tadalafil in Entadfi™ capsules for quality control.

Finasteride and testosterone are the drugs most linked to male infertility, but many other potential drugs may be under-reported.

Some drugs may increase the risk of obstructive sleep apnea, while others like certain biologics might decrease it.

Younger people (median age 35) experience more PFS-like symptoms with 1mg finasteride; more research needed.

The anti-viral drug Elvitegravir may protect brain cells from damage related to neurodegenerative diseases.

New, eco-friendly methods accurately measure TDF and FNS in a new urologic medication.

The study developed accurate, precise, and environmentally friendly methods to measure Finasteride and Tadalafil in a new FDA-approved combination.

Finasteride increases risk of sleep apnea and insomnia.

Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.

Finasteride and minoxidil are effective FDA-approved treatments for androgenetic alopecia.

The new FDA labeling rules provide more detailed drug safety information for pregnant and breastfeeding women, but more data is needed on the risks of many dermatologic drugs.

JAK inhibitors like baricitinib are a new FDA-approved treatment for alopecia areata, but safety data is incomplete.

No current patient-reported outcome measure fully meets FDA requirements for alopecia treatments.

The FDA approved the first gene therapy for a blood disorder after overcoming early challenges and demonstrating patient benefits.

No FDA-approved treatments for chemotherapy-induced hair loss existed in 2006; more research was needed.

The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.

There are no FDA-approved treatments for Alopecia Areata, and current options have varying success and relapse rates.

Deoxycholic acid is FDA-approved for reducing submental fat, but its mechanisms are not fully understood.

Minoxidil and finasteride are FDA-approved treatments for male hair loss, but off-label use of oral minoxidil, dutasteride, and higher doses of finasteride and minoxidil is increasing.

Minoxidil is the only FDA-approved treatment for female hair loss, with other potential treatments needing more research for effectiveness.

The document concluded that FDA-approved treatments like minoxidil and finasteride are effective for hair loss, while the effectiveness of natural remedies and other non-approved treatments is not well-supported by evidence.

The document concludes that proper diagnosis and FDA-approved treatments for different types of hair loss exist, but treatments for severe cases often fail and future improvements may focus on hair follicle stem cells.

Treat genetic hair loss early with FDA-approved medications and consider hair transplantation.